Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00065312 | An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes | PHASE2 | COMPLETED | - | — | — | - | - | Jul 19, 2006 | 42 | United States |
| Name | Type | Description |
|---|---|---|
| naveglitazar | DRUG | - |
Inclusion Criteria: * Diagnosis of Type 2 Diabetes for at least 3 months. * Diabetes managed with diet and exercise alone or with either metformin or sulfonylurea alone as an adjunct to diet and exercise. * Diabetes therapy must be unchanged for at least 3 months prior to screening. * Females must ...